Dr. Wallace Wu focuses on patent litigation, post issuance patent office proceedings, and patent clearance. In particular, he concentrates on cases involving life sciences, biological and small molecule drugs, polymers, and medical devices.

Dr. Wu has represented clients in district courts across the country and before the Court of Appeals for the Federal Circuit. He also is admitted to practice before the Patent and Trademark Office, and has extensive experience in patent office proceedings, portfolio evaluation, and due diligence analysis. Prior to entering law school, he completed a postdoctoral fellowship at Massachusetts Institute of Technology in the field of molecular biology.

Experience

  • Boston Scientific in a patent infringement action involving the use of antiproliferative drugs to treat restenosis. The District Court granted summary judgment of patent invalidity, which was affirmed by the Federal Circuit. 2012 WL 175023; 720 F.3d 1380 (Fed. Cir. 2013).
  • GenSpera in an inventorship dispute relating to peptide prodrug technology. The case resulted in summary judgment for GenSpera on all claims and counterclaims.
  • Boston Scientific in a patent infringement action involving drug-eluting stent devices and drug analogs. The District Court granted summary judgement of patent invalidity, which was affirmed by the Federal Circuit. 679 F. Supp. 2d 539 (D.Del. 2010); 647 F.3d 1353 (Fed. Cir. 2011).
  • Amgen in a patent infringement action involving Granulocyte Colony-Stimulating Factors. The case resulted in judgment of infringement and permanent injunction.
  • Hologic in a patent infringement action involving detection of noncoding DNA sequences. The case settled before trial.
  • GE Healthcare in a patent infringement action involving reverse transcriptase enzymes and random primer amplification technology. The case settled before trial.
  • GE Healthcare in a patent infringement action involving affinity chromatography instruments. The court granted summary adjudication on patent invalidity. The decision was affirmed by the Federal Circuit. 490 F.3d 946 (Fed. Cir. 2007).

Perspectives

Amgen v. Sandoz: Federal Circuit Rules That the BPCIA's "Patent Dance" is Optional
Arnold & Porter Advisory
The Brave New World Of Biosimilars In The US

MCLE

IP/Technology Year in Review and Forecast: Protecting Your Company's IP Position
Arnold & Porter Webcast

Credentials

Education
  • JD, Santa Clara University School of Law, 2001
  • PhD, Biochemistry, Massachusetts Institute of Technology, 1996
  • BS, Chemistry, The University of Kansas, 1991, High Distinction
Admissions
  • California
  • US Court of Appeals for the Federal Circuit
  • US District Court, Central District of California
  • US District Court, Northern District of California
  • US District Court, Southern District of California
  • US District Court, Eastern District of Texas
  • US Patent and Trademark Office
Overview

Email Disclaimer